Key result
Genetic or pharmacologic enhancement of GATA-4 prevents cardiomyocyte apoptosis and doxorubicin-induced cardiotoxicity, indicating it is an essential antiapoptotic survival factor.
Population
Differentiated, postnatal cardiomyocytes and mouse heterozygotes for a null Gata4 allele exposed to…
Design
Preclinical
Authors
Loading...
Supports GATA-4 targeting for cardioprotection; leaves open clinical translation from animal data.
GATA-4 acts as a crucial antiapoptotic survival factor in the adult heart, and its enhancement protects against doxorubicin-induced cardiotoxicity.
Aries et al. (2004) studied Doxorubicin-induced cardiotoxicity. Genetic or pharmacologic enhancement of GATA-4 was evaluated on Cardiomyocyte apoptosis and drug-induced cardiotoxicity. Genetic or pharmacologic enhancement of GATA-4 prevents cardiomyocyte apoptosis and doxorubicin-induced cardiotoxicity, indicating it is an essential antiapoptotic survival factor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: